Science Explorer Back to mapMap
Discussion
Institution · Prevent Alzheimer’s Disease 2020

Most cited papers from Prevent Alzheimer’s Disease 2020

Prevent Alzheimer’s Disease 2020

What are the most cited papers from Prevent Alzheimer’s Disease 2020?

The most cited paper from Prevent Alzheimer’s Disease 2020 is "The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease" (Marilyn S. Albert, Steven T. DeKosky, Dennis W. Dickson et al., 2011), with 10,419 citations. Next come "Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria" (1,953) and "The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease" (1,911).

Showing 50 of 60 papers. Every paper with more than 57 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Marilyn S. Albert, Steven T. DeKosky, Dennis W. Dickson et al. · Alzheimer s & Dementia Open access 22 Apr 2011 10,419
2 Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria Bruno Dubois et al. · Alzheimer s & Dementia Open access Mar 2016 1,953
3 The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease Harald Juergen Hampel, M.‐Marsel Mesulam, A. Claudio Cuello et al. · Brain Open access 26 Apr 2018 1,911
4 Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction Daniel A. Nation, Melanie D. Sweeney, Axel Montagne et al. · Nature Medicine Open access 8 Jan 2019 1,796
5 Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis Yasser Iturria‐Medina et al. · Nature Communications Open access316 authors 21 Jun 2016 1,244
6 Sleep Quality and Preclinical Alzheimer Disease Yo‐El S. Ju, Jennifer McLeland, Cristina D. Toedebusch et al. · JAMA Neurology Open access 11 Mar 2013 763
7 Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers Giovanni Battista Frisoni et al. · The Lancet Neurology Open access 11 Jul 2017 646
8 Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study Brian Andrew Gordon et al. · The Lancet Neurology Open access Feb 2018 632
9 Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis Vitaliy Ovod, Kara N. Ramsey, Kwasi G. Mawuenyega et al. · Alzheimer s & Dementia Open access 19 Jul 2017 618
10 Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference Alexandra L. Young et al. · Nature Communications Open access380 authors 9 Oct 2018 613
11 Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease John C. Morris, Catherine M. Roe, Elizabeth Grant et al. · Archives of Neurology Open access Dec 2009 478
12 Predicting Alzheimer’s disease progression using multi-modal deep learning approach Garam Lee et al. · Scientific Reports Open access315 authors 13 Feb 2019 415
13 Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research Harald Juergen Hampel, M.‐Marsel Mesulam, A. Claudio Cuello et al. · The Journal of Prevention of Alzheimer s Disease Open access 2019 368
14 Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology Taylor W. Schmitz et al. · Nature Communications Open access313 authors 4 Nov 2016 365
15 Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE Scott Ayton et al. · Nature Communications Open access314 authors 19 May 2015 332
16 Preventing dementia by preventing stroke: The Berlin Manifesto Vladimir Hachinski et al. · Alzheimer s & Dementia Open access Jul 2019 331
17 Advances in the prevention of Alzheimer's disease and dementia Alina Solomon, Francesca Mangialasche, Edo Richard et al. · Journal of Internal Medicine Open access Mar 2014 319
18 Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease Suzanne Elizabeth Schindler et al. · Nature Reviews Neurology ReviewOpen access 12 Jun 2024 296
19 Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology Erin L. Abner, Peter T. Nelson, Richard J. Kryscio et al. · Alzheimer s & Dementia Open access 23 Jan 2016 235
20 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride Neurotoxicity Is Attenuated in Mice Overexpressing Bcl-2 Lichuan Yang, Russell T. Matthews, Jörg Bernhard Schulz et al. · Journal of Neuroscience Open access 15 Oct 1998 199
21 Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology Anne M. Fagan, Leslie M. Shaw, Chengjie Xiong et al. · Archives of Neurology Open access 10 May 2011 191
22 Angiotensin-Converting Enzyme Converts Amyloid β-Protein 1–42 (Aβ 1–42 ) to Aβ 1–40 , and Its Inhibition Enhances Brain Aβ Deposition Kun Zou, Haruyasu Yamaguchi, Hiroyasu Akatsu et al. · Journal of Neuroscience Open access 8 Aug 2007 188
23 APOE genotype regulates pathology and disease progression in synucleinopathy Albert A. Davis, Casey E. Inman, Zachary M. Wargel et al. · Science Translational Medicine Open access 5 Feb 2020 187
24 Comparison of a single‐channel EEG sleep study to polysomnography Brendan P. Lucey, Jennifer McLeland, Cristina D. Toedebusch et al. · Journal of Sleep Research Open access 2 Jun 2016 159
25 Polygenic risk score of sporadic late‐onset Alzheimer's disease reveals a shared architecture with the familial and early‐onset forms Carlos Cruchaga, Jorge L. Del‐Aguila, Benjamin A. Saef et al. · Alzheimer s & Dementia Open access 21 Sep 2017 155
26 Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force Bruno J. Vellas et al. · Alzheimer s & Dementia 26 Jun 2013 145
27 Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020 Harald Juergen Hampel, Simone Lista, Stefan Johannes Teipel et al. · Biochemical Pharmacology 22 Nov 2013 139
28 Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology Xinpeng Shen et al. · Scientific Reports Open access309 authors 19 Feb 2020 137
29 Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot Harald Juergen Hampel, Simone Lista, Zaven S. Khachaturian · Alzheimer s & Dementia 28 Jun 2012 136
30 Soluble Amyloid-beta Aggregates from Human Alzheimer’s Disease Brains Thomas J. Esparza, Norelle C. Wildburger, Hao Jiang et al. · Scientific Reports Open access 5 Dec 2016 133
31 Sleep Deprivation Affects Tau Phosphorylation in Human Cerebrospinal Fluid Nicolas R. Barthélemy, Haiyan Liu, William Lu et al. · Annals of Neurology Open access 14 Feb 2020 130
32 Non-coding variability at the APOE locus contributes to the Alzheimer’s risk Xiaopu Zhou et al. · Nature Communications Open access319 authors 25 Jul 2019 125
33 Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease María C. Carrillo, H. Robert Brashear, Veronika Logovinsky et al. · Alzheimer s & Dementia 11 Feb 2013 122
34 Clinical Implementation of Prolonged Liver Preservation and Monitoring Through Normothermic Machine Perfusion in Liver Transplantation Benno Cardini et al. · Transplantation 4 May 2020 119
35 The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory Nicolai Franzmeier et al. · Nature Communications Open access308 authors 16 Apr 2019 118
36 Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease Michelle M. Mielke et al. · Alzheimer s & Dementia Open access Oct 2024 117
37 Assessment of cognition in mild cognitive impairment: A comparative study Peter Jeffrey Snyder, Colleen E. Jackson, Ronald Carl Petersen et al. · Alzheimer s & Dementia Open access May 2011 106
38 Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics Yogatheesan Varatharajah et al. · Scientific Reports Open access309 authors 19 Feb 2019 104
39 Concordance of Lumipulse cerebrospinal fluid t‐tau/Aβ42 ratio with amyloid PET status June M. Kaplow, Manu Leen Jef Vandijck, Julia D. Gray et al. · Alzheimer s & Dementia Open access 2020 91
40 Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease Niklas Mattsson et al. · Alzheimer s & Dementia Open access 27 Mar 2018 91
41 Apolipoprotein E ε4 Allele Is Unrelated to Cognitive or Functional Decline in Alzheimer’s Disease: Retrospective and Prospective Analysis Timothy Kleiman, Kristina F. Zdanys, Benjamin T. Black et al. · Dementia and Geriatric Cognitive Disorders 2006 91
42 Cross‐sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology Brian Andrew Gordon, Austin A. McCullough, Shruti Mishra et al. · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring Open access 2018 81
43 Mapping the Road Forward in Alzheimer’s Disease David M. Holtzman, Alison Goate, Jeffery W. Kelly et al. · Science Translational Medicine 21 Dec 2011 80
44 Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge Hugo Geerts, Penny A. Dacks, Viswanath Devanarayan et al. · Alzheimer s & Dementia Open access 27 May 2016 79
45 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease Keith N. Fargo et al. · Alzheimer s & Dementia Open access Oct 2014 76
46 A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid Melanie D. Sweeney, Abhay P. Sagare, Maricarmen Pachicano et al. · Alzheimer s & Dementia Open access 16 Apr 2020 74
47 Effect of cognitive fluctuation on neuropsychological performance in aging and dementia Adriana Escandon, Noor J. Al-Hammadi, James E. Galvin · Neurology Open access 18 Jan 2010 74
48 Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction Xiaopu Zhou et al. · Communications Medicine Open access327 authors 6 Apr 2023 72
49 Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status Xue‐Ning Shen et al. · Translational Psychiatry Open access463 authors 13 Nov 2021 71
50 Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease Qing Wang, Yong Wang, Jingxia Liu et al. · NeuroImage Clinical Open access 2019 71

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.